JP2022008641A5 - - Google Patents

Download PDF

Info

Publication number
JP2022008641A5
JP2022008641A5 JP2021159462A JP2021159462A JP2022008641A5 JP 2022008641 A5 JP2022008641 A5 JP 2022008641A5 JP 2021159462 A JP2021159462 A JP 2021159462A JP 2021159462 A JP2021159462 A JP 2021159462A JP 2022008641 A5 JP2022008641 A5 JP 2022008641A5
Authority
JP
Japan
Prior art keywords
composition
level
sample
fold
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021159462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022008641A (ja
JP7208323B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2015/023038 external-priority patent/WO2015148950A1/en
Application filed filed Critical
Publication of JP2022008641A publication Critical patent/JP2022008641A/ja
Publication of JP2022008641A5 publication Critical patent/JP2022008641A5/ja
Application granted granted Critical
Publication of JP7208323B2 publication Critical patent/JP7208323B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021159462A 2014-03-28 2021-09-29 L-2-ヒドロキシグルタル酸及びストレス誘発性代謝 Active JP7208323B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461972091P 2014-03-28 2014-03-28
US61/972,091 2014-03-28
PCT/US2015/023038 WO2015148950A1 (en) 2014-03-28 2015-03-27 L-2-hydroxyglutarate and stress induced metabolism
JP2017502940A JP6953305B2 (ja) 2014-03-28 2015-03-27 L−2−ヒドロキシグルタル酸及びストレス誘発性代謝

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017502940A Division JP6953305B2 (ja) 2014-03-28 2015-03-27 L−2−ヒドロキシグルタル酸及びストレス誘発性代謝

Publications (3)

Publication Number Publication Date
JP2022008641A JP2022008641A (ja) 2022-01-13
JP2022008641A5 true JP2022008641A5 (https=) 2022-02-14
JP7208323B2 JP7208323B2 (ja) 2023-01-18

Family

ID=54196451

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017502940A Expired - Fee Related JP6953305B2 (ja) 2014-03-28 2015-03-27 L−2−ヒドロキシグルタル酸及びストレス誘発性代謝
JP2021159462A Active JP7208323B2 (ja) 2014-03-28 2021-09-29 L-2-ヒドロキシグルタル酸及びストレス誘発性代謝

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017502940A Expired - Fee Related JP6953305B2 (ja) 2014-03-28 2015-03-27 L−2−ヒドロキシグルタル酸及びストレス誘発性代謝

Country Status (6)

Country Link
US (2) US10450596B2 (https=)
EP (1) EP3122893B1 (https=)
JP (2) JP6953305B2 (https=)
AU (1) AU2015237241B2 (https=)
CA (1) CA2943823C (https=)
WO (1) WO2015148950A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075065A1 (en) 2011-11-18 2013-05-23 Memorial Sloan-Kettering Cancer Center 2-hydroxyglutarate as a biomarker for chronic hypoxia
US10450596B2 (en) 2014-03-28 2019-10-22 Memorial Sloan-Kettering Cancer Center L-2-hydroxyglutarate and stress induced metabolism
US20200375963A1 (en) * 2017-02-10 2020-12-03 Health Research, Inc. Targeting mitochondrial complex ii to reduce effects of chronic hypoxia
US10500318B1 (en) * 2018-07-03 2019-12-10 Temple Therapeutics BV Dosing regimens for treating hypoxia-associated tissue damage
JP6977999B2 (ja) * 2018-08-22 2021-12-08 国立大学法人京都大学 胚培養培地、及び胚培養方法
FR3097739B1 (fr) * 2019-06-25 2022-03-04 Lnc Therapeutics Bactéries du microbiote intestinal et composition en contenant pour son utilisation dans la prévention et/ou le traitement de maladies caractérisées par l’excès de 2-hydroxyglutarate
CN112830958B (zh) * 2021-02-05 2022-06-14 山东大学 一种特异性响应于d-2-羟基戊二酸的转录调控因子及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20060084123A1 (en) 2001-12-13 2006-04-20 Harris Adrian L MN and hypoxia
JP2006507510A (ja) * 2002-11-21 2006-03-02 インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 組織低酸素症の体液マーカー
WO2009086215A2 (en) 2007-12-21 2009-07-09 Wyeth Pathway analysis of cell culture phenotypes and uses thereof
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
SE534542C2 (sv) 2009-09-30 2011-09-27 Calmark Sweden Ab Testsystem för bestämning av hypoxiutlöst cellskada
WO2011050211A2 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US20120202883A1 (en) * 2011-01-20 2012-08-09 Duke University Effects of idh1 and idh2 mutations on the cellular metabolome
WO2013075065A1 (en) * 2011-11-18 2013-05-23 Memorial Sloan-Kettering Cancer Center 2-hydroxyglutarate as a biomarker for chronic hypoxia
CA2853202A1 (en) * 2011-12-09 2013-06-13 Metabolon, Inc. Biomarkers for kidney cancer and methods using the same
US8977473B2 (en) 2012-08-29 2015-03-10 Caterpillar Inc. Pressure control strategy for dual fuel compression ignition engine and machine using same
US10450596B2 (en) 2014-03-28 2019-10-22 Memorial Sloan-Kettering Cancer Center L-2-hydroxyglutarate and stress induced metabolism

Similar Documents

Publication Publication Date Title
JP2022008641A5 (https=)
Schaupp et al. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis
Arron et al. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma
Malerba et al. Exhaled nitric oxide as a biomarker in COPD and related comorbidities
JP6755241B2 (ja) 新規分子バイオマーカーを使用して慢性閉塞性肺疾患(copd)を診断する方法
JP2017520774A5 (https=)
Palmiere et al. Endocan measurement for the postmortem diagnosis of sepsis
JP2025019061A (ja) 術後有害事象の診断または予後
Wu et al. Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients
US12517137B2 (en) Methods of treating or preventing serious symptoms from COVID-19 infection
JP2018162303A (ja) 感染の治療および予防におけるセラミドレベル
JP2017519523A (ja) 新規分子バイオマーカーを使用して慢性閉塞性肺疾患(copd)を診断する方法
Molanaei et al. Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation
Kotlinska-Hasiec et al. Disturbance in venous outflow from the cerebral circulation intensifies the release of blood-brain barrier injury biomarkers in patients undergoing cardiac surgery
Nakamura et al. Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock
CN112424609A (zh) 卒中的血液生物标志物
JPWO2007094394A1 (ja) 意識障害患者における病態の検出方法及び検出用キット
Loonat et al. p38γ MAPK contributes to left ventricular remodeling after pathologic stress and disinhibits calpain through phosphorylation of calpastatin
Lozhkina et al. Ceramides As Potential New Predictors of the Severity of Acute Coronary Syndrome in Conjunction with SARS-CoV-2 Infection
Jain Biomarkers of pulmonary diseases
CN116359515A (zh) 检测和治疗肺高压的方法
Morishima et al. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor
Cai et al. Resistive spontaneous breathing exacerbated lipopolysaccharide-induced lung injury in mice
JP2017533431A (ja) 細気管支炎後の喘息の診断のためのマーカーおよびその用途
US11634717B2 (en) DNA aptamer specifically binding to TB7.7, and use thereof